uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Early death among head and neck cancer patients
Linkoping Univ, Dept Clin & Expt Med, Dept Otorhinolaryngol, Linkoping, Sweden..
Finnish Canc Registry, FIN-00170 Helsinki, Finland..
Karolinska Inst, Div Ear Nose & Throat Dis Intervent & Technol, Dept Clin Sci, Stockholm, Sweden.;Karolinska Hosp, S-10401 Stockholm, Sweden.;Univ Helsinki, Dept Otorhinolaryngol Head & Neck Surg, Helsinki, Finland.;Helsinki Univ Hosp, FI-00029 Helsinki, Hus, Finland..
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Surgical Sciences, Otolaryngology and Head and Neck Surgery.
2016 (English)In: Current Opinion in Otolaryngology & Head and Neck Surgery, ISSN 1068-9508, E-ISSN 1531-6998, Vol. 24, no 2, p. 115-120Article, review/survey (Refereed) Published
Resource type
Text
Abstract [en]

Purpose of reviewManagement of advanced head and neck cancer (HNC) is characterized by high mortality. Furthermore, the treatment involves significant burden to patients and high costs to healthcare systems. Recognizing the risks of early death in patients with a high probability of noncurable disease is important for each individual treatment decision-making. It is thus critical to consider the benefits and side-effects of the planned treatment in relation to the expected survival and to discuss these factors with the patient. However, only few studies have documented early death in HNC patients, that is, during the first posttreatment 6 months. We performed a systematic literature review to find the incidence of this phenomenon and to outline the probable cause.Recent findingsEarly mortality in patients with HNC can be explained either by direct effect of malignant disease, may be related to comorbidities, or secondary to the treatment. These factors act together resulting in expected or unexpected early death.SummaryThe present review provides information on the mechanisms leading to early phase mortality (<6 months) after management of HNC. It also reports the incidence of this phenomenon among Finnish and Swedish patient populations.

Place, publisher, year, edition, pages
2016. Vol. 24, no 2, p. 115-120
Keyword [en]
chemotherapy, mortality, radiotherapy, surgery, survival
National Category
Otorhinolaryngology
Identifiers
URN: urn:nbn:se:uu:diva-298949DOI: 10.1097/MOO.0000000000000236ISI: 000371888600005PubMedID: 26735585OAI: oai:DiVA.org:uu-298949DiVA: diva2:948684
Available from: 2016-07-13 Created: 2016-07-12 Last updated: 2017-11-28Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMed

Authority records BETA

Laurell, Göran

Search in DiVA

By author/editor
Laurell, Göran
By organisation
Otolaryngology and Head and Neck Surgery
In the same journal
Current Opinion in Otolaryngology & Head and Neck Surgery
Otorhinolaryngology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 346 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf